About Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare liver diseases. The company aims to address significant unmet medical needs through its pipeline of novel therapeutic candidates, leveraging its expertise in drug discovery and development. Mirum's commitment to advancing patient care is evident in its efforts to deliver effective solutions that improve the quality of life for individuals suffering from conditions related to liver dysfunction. Through rigorous research and clinical studies, Mirum strives to contribute to the advancements in treatments that target these often overlooked diseases. Read More
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV) to Mirum’s portfolio of rare liver programs. This acquisition is expected to advance Mirum’s leadership in rare disease, build on its deep expertise in rare liver disorders and add a fourth potential registrational readout for the company over the next 18 months.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,500 shares of common stock and 27,950 restricted stock units (“RSUs”) to 11 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs will be shared during the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place November 7-11, 2025, in Washington, D.C.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress.
Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 45,800 shares of common stock and 22,850 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on September 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,820 shares of common stock and 5,390 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced in the second quarter of 2026.
